New PCS codes were released late last week and are effective Aug. 1, 2020. The codes are considered V37.2. There are 12 new procedure codes, and they are related to COVID-19.
The good news is that these procedure codes are not designated as DRG OR procedures, so they do not affect the MS-DRG assignment. They can all be found in the New Technology section and Anatomic Region body system of ICD-10-PCS. Six new procedures incorporate three new substances related to treating COVID-19: Remdesivir Anti-Infective, Sarilumab, and Tocilizumab.
There have been studies regarding Remdesivir’s effectiveness in treating COVID-19. The early results show that this drug has shortened patients’ recovery time. Sarilumab is also known as Kevzara, and is used to treat rheumatoid arthritis. The clinical trials related to this drug have been stopped due to disappointing results. Tocilizumab is another drug that is used to treat rheumatoid arthritis, as well as cytokine release syndrome. The initial results of the clinical trials are promising in reducing the risk of invasive mechanical ventilation for patients who have pneumonia with COVID-19.
The approach for these substances is percutaneous, and includes body parts of central and peripheral vein. The root operation is Introduction and the Qualifier is New Technology Group 5, which indicates the 2020 fiscal year.
Two new codes are for the transfusion of convalescent plasma, non-autologous. This substance is found in patients who have recovered from COVID-19 and have antibodies for the disease. The plasma is separated from the blood of a recovered patient who has not had any COVID-19 symptoms for at least 14 days. The convalescent plasma is then transfused into a COVID-19 patient. This treatment is still in clinical trials, without any posted results.
These new codes use the root operation of Transfusion in the New Technology Section. The Approach is percutaneous, with Body Parts of central and peripheral vein. The Qualifier is New Technology Group 5.
Another new development in this release of new PCS codes is the creation of codes for the substance of “Other New Technology Therapeutic Substance.” It is thought that this alternative could be used for new substances that do not have an appropriate other alternative. The approaches include percutaneous and external. The body parts are central vein, peripheral vein, mouth, and pharynx, along with subcutaneous tissue. The Qualifier is New Technology Group 5.
These new codes were effective Aug. 1, 2020, but encoder companies are busy trying to update their encoder software. While you are waiting for the update, please prepare for these new codes. Here are some action items:
This late release of new procedure codes is unprecedented, but we are not usually immersed in a pandemic. Take some time to determine how you want the information to be used. Involve other people at your facility before you make decisions on how to utilize these new codes. Remember that the codes do not affect MS-DRG assignment, so there is no rush.
Think of the release of these new codes as Christmas in July: the gift of new PCS codes.
-19
.
Programming Note:
Laurie Johnson is a permanent panelist on Talk Ten Tuesdays. Listen to her coding report during Talk Ten Tuesdays, 10-10:30 a.m. EST.
Denials have been on my mind for the last few weeks – specifically, how do we prevent them? According to the Public Broadcasting Service (PBS),
Action taken by payers is seen as increasing. Having been on the receiving end of audits, and also having been an individual who has conducted
Please log in to your account to comment on this article.
Dr. Ronald Hirsch provides tried-and-true strategies and insight into outpatient in hospital bed stays including determining the applicable definition, who uses it, and when and how to bill for this circumstance, solidified with concrete case examples and expert insight.
Practical solutions for CDM departments to protect your hospital’s revenue.
This webcast teaches hospitals how to comply with CMS price transparency rules and compare their rates with peer hospitals. It covers creating a compliant machine-readable file, comparing negotiated rates, and improving pricing decisions.
The No Surprises Act (NSA) presents a challenge for hospitals and providers who must provide Good Faith Estimates (GFEs) for all schedulable services for self-pay and uninsured patients. Compliance is necessary, but few hospitals have been able to fully comply with the requirements despite being a year into the NSA. This webcast provides an overview of the NSA/GFE policy, its impact, and a step-by-step process to adhere to the requirements and avoid non-compliance penalties.
This expert-guided webcast will showcase tips for providers to ensure appropriate capture of the work performed for a visit. Comprehensive examples will be given that demonstrate documentation gaps and how to educate providers on the documentation necessary to appropriately assign a level of service. You will gain clarification on answers regarding emergency department and urgent care coding circumstances as well as a review of how/when it is appropriate to code for E&M in radiology and more.
Set yourself up for financial and compliance success with expert guidance that breaks down the impactful changes including MS-DRG methodology, surgical hierarchy updates, and many new technology add-on payments (NTAPs). Identify areas of potential challenge ahead of time and master solutions for all 2024 Proposed IPPS changes.
Do you struggle with selecting and appending the correct modifier for your medical claims? Join our must-attend webinar, “Mastering Modifier Usage: Preventing Denials and Ensuring Compliance” to reduce claim denials and improve your reimbursement rates.
Kay Piper reviews the guidance and updates coders and CDISs on important information in the AHA’s fourth quarter 2023 ICD-10-CM/PCS Quarterly Coding Clinic in an easy to access on-demand webcast.
Copyright © 2023 ICD10monitor. Powered by MedLearn Media.
